A large, well-capitalized peer is apparently interested in a partnership deal with the company. The media outlet in question ...

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the 30 stocks expected to beat the market by 20 percentage points this ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

Fintel reports that on July 1, 2025, UBS initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a Buy recommendation.

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...

Bengaluru: AstraZeneca is reportedly in discussions with Summit Therapeutics to license an experimental lung cancer drug in a ...

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...

Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...

Summit Therapeutics Inc. (NASDAQ: SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, ...